Ashray Gunjur

机构：Wellcome Sanger Institute, Austin Health · ORCID：0000-0001-9713-1872

发表论文 63 篇 · 总被引 583 次 · h-index 12

代表论文

• A gut microbial signature for combination immune checkpoint blockade across cancer types (2024 · Nature Medicine · 被引 143)
• Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers (2025 · JAMA Oncology · 被引 18)
• Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers (2025 · JAMA Oncology · 被引 5)
• Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance (2024 · eJHaem · 被引 5)
• 282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer (2024 · Annals of Oncology · 被引 3)
• The molecular cartography of malignant and benign sebaceous tumours (2025 · Nature Communications · 被引 2)